Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Drug Development Collaborations - Additional Information (Detail)

v2.4.0.8
Significant Strategic Drug Development Collaborations - Additional Information (Detail) (USD $)
0 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Jan. 23, 2014
Mar. 31, 2014
Serum Institute of India Limited [Member]
Mar. 31, 2013
Serum Institute of India Limited [Member]
Dec. 31, 2012
Serum Institute of India Limited [Member]
Product
Mar. 31, 2014
Serum Institute of India Limited [Member]
Development and Manufacturing Arrangement [Member]
Jan. 31, 2014
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Mar. 31, 2014
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Mar. 31, 2013
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Jan. 31, 2014
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Maximum [Member]
Mar. 31, 2014
SynBio LLC [Member]
Mar. 31, 2013
SynBio LLC [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Potential development, regulatory, sales and deadline extension receipts                 $ 100,000,000    
Issuance of common stock, Shares 132,545,504         10,695,187          
Issuance of common stock           10,000,000          
Agreement amended period           2014-01          
Royalties expiration period             10 years        
Royalties expiration description             The Company's right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in that particular country.        
Research and development recognized as revenue             0 0      
Share ownership percentage   9.40% 10.60%       8.90% 1.80%   40.30% 45.30%
Description and terms of license and arrangements   In the period from 2004 through 2011, the Company entered into and amended certain license and supply agreements with Serum Institute. The original license agreement with Serum Institute was a collaborative Development and Manufacturing Arrangement ("DMA") to develop agreed upon potential commercial product candidates using the Company's PolyXen technology                  
Number of potential commercial product       14              
License amendment description   Following the 2011 amendment, Serum Institute retained an exclusive license to use the Company’s PolyXen® technology to research and develop one potential commercial product, Polysialylated Erythropoietin (“PSA-EPO”). Serum Institute will be responsible for conducting all pre-clinical and clinical trials required to achieve regulatory approvals within the certain predetermined territories at Serum Institute’s own expense. The royalty payment schedule based on net revenues on the future commercial sales of PSA-EPO under the DMA was also modified as a result of the 2011 amendment.                  
Royalty revenue or expense   0 0                
Milestone or other research-related payments due under the DMA         $ 0